Merck KGaA Q3 2025 Earnings Report

Merck KGaA EPS Results

• Actual EPS: $0.81
• Consensus EPS: $0.54
• Beat/Miss: Beat by +$0.27
• One Year Ago EPS: N/A

Merck KGaA Revenue Results

• Actual Revenue: $6.17 billion
• Expected Revenue: $6.08 billion
• Beat/Miss: Beat by +$86.79 million
• YoY Revenue Growth: N/A

Merck KGaA Announcement Details

• Quarter: Q3 2025
• Date: 11/13/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Merck KGaA (OTCMKTS:MKKGY), Darmstadt, Germany, commonly referred to as Merck Group, is a multinational science and technology company with origins dating back to 1668. The company develops and manufactures products and technologies across healthcare, life science and electronics applications. It is distinct from the U.S. pharmaceutical company Merck & Co.; Merck KGaA is a European group headquartered in Darmstadt and is publicly listed in Germany with an OTC American depositary receipt available under the symbol MKKGY.

Merck’s Healthcare business develops prescription medicines and related services focused on areas such as oncology, immunology, neurology (including therapies for multiple sclerosis) and fertility. The Life Science division supplies reagents, lab consumables, filtration and chromatography solutions, and bioprocessing technologies to research institutions and biopharmaceutical manufacturers — operations that include the MilliporeSigma brand in the United States and Canada following the acquisition of Sigma‑Aldrich. The Electronics business produces high‑performance materials and specialty chemicals used in semiconductor fabrication, display technologies and other advanced industrial applications.

The company operates globally, serving customers across Europe, the Americas, Asia and other regions through manufacturing sites, research centers and commercial affiliates. Since May 2021 Merck KGaA has been led by Chair of the Executive Board and CEO Belén Garijo. Merck emphasizes integrated R&D and partnerships to support pharmaceutical development, laboratory science and materials innovation, positioning itself as a diversified supplier to healthcare, research and high‑technology industries.